Akèy › Limfom Selil-T
Etid klinik pou Limfom Selil-T ap rekrite nan Etazini
35 etid pou Limfom Selil-T ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY13 etid
- Philadelphia, PA10 etid
- Boston, MA9 etid
- Baldwin Park, CA9 etid
- Atlanta, GA8 etid
- Houston, TX8 etid
- Columbus, OH6 etid
- Rochester, MN6 etid
- Chicago, IL6 etid
- Seattle, WA6 etid
- New Haven, CT5 etid
- Miami, FL5 etid
- St. Louis, MO4 etid
- Ann Arbor, MI4 etid
- Scottsdale, AZ4 etid
- Cedar Rapids, IA4 etid
- Baltimore, MD4 etid
- Portland, OR4 etid
- Charlottesville, VA4 etid
- Durham, NC4 etid
- New Rochelle, NY3 etid
- East Norwalk, CT3 etid
- Queens, NY3 etid
- Edison, NJ3 etid
- Staten Island, NY3 etid
- San Diego, CA3 etid
- Omaha, NE3 etid
- San Francisco, CA3 etid
- Aurora, CO3 etid
- Tampa, FL3 etid
- Los Angeles, CA3 etid
- Rochester, NY3 etid
- Milwaukee, WI3 etid
- Indianapolis, IN3 etid
- Salt Lake City, UT3 etid
- Charlotte, NC3 etid
- Madison, WI3 etid
- Minneapolis, MN3 etid
- Denver, CO3 etid
- Cincinnati, OH3 etid
Pa eta
- Arizona5 etid
- Colorado6 etid
- Connecticut5 etid
- Florid8 etid
- Georgia8 etid
- Illinois7 etid
- Indiana3 etid
- Iowa4 etid
- Kalifòni13 etid
- Maryland4 etid
- Massachusetts9 etid
- Michigan5 etid
- Minnesota9 etid
- Missouri4 etid
- Nebraska3 etid
- New Jersey4 etid
- New York15 etid
- North Carolina6 etid
- Ohio8 etid
- Oklahoma3 etid
- Oregon4 etid
- Pennsylvania12 etid
- Texas9 etid
- Utah3 etid
- Virginia5 etid
- Washington6 etid
- Wisconsin5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06561048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT04752826Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06724237A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05010005A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06854653Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04803201A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07382817CD45BE-HSPC + CART-45 Cells
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT07451054Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Ap rekriteFaz 2
Laj 1 a 18 · Tout sèks · Mizajou Aug 10, 2026 · NCT06390319Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07750886Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07293403Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT03011814Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Ap rekriteFaz 1
Laj 0 a 29 · Tout sèks · Mizajou Jul 7, 2026 · NCT06934382Allo HSCT Using RIC and PTCy for Hematological Diseases
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Jul 6, 2026 · NCT05805605Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT03501576Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT06508463CD4CAR for CD4+ Leukemia and Lymphoma
Ap rekriteFaz 1
Laj 12 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT03829540A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 16, 2026 · NCT05463263Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT05313243A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT03017820Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 5, 2026 · NCT07278856A Registry for People With T-cell Lymphoma
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 20, 2026 · NCT05978141Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 11, 2026 · NCT07225985Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.